Jinwon Life Sciences Subsidiary VGXI Holds Inauguration Ceremony for New Factory

Exterior view of VGXI headquarters. / Photo by Jinwon Life Sciences

[Asia Economy Reporter Jang Hyowon] On the 11th, Jinwon Life Sciences announced that its subsidiary VGXI, a plasmid DNA contract development and manufacturing organization (CDMO), held a completion ceremony for a new factory built at Deison Technology Park in Conroe, Texas, USA, on the 7th.

The completion ceremony was attended by U.S. House Representative Kevin Brady, Consul General Ahn Myungsoo of the Consulate General of the Republic of Korea in Houston, Frank Holley, CEO of the construction company BE&K, officials from Conroe, representatives from VGXI’s client companies and business partners, Ann Tanabe, CEO of BioHouston, and other representatives of Texas-based bio companies and industry stakeholders.

A company official stated, “Starting from the completion ceremony, with a flexible fermentation capacity exceeding a total of 3,000 liters ranging from 10 liters to 1,500 liters, we can perform more differentiated and large-scale high-quality plasmid DNA contract development and manufacturing, thereby meeting diverse customer demands. Additionally, since mRNA bulk production is now possible, further revenue growth is expected.”

Park Younggeun, CEO of Jinwon Life Sciences, said, “The new factory, VGXI’s new headquarters, was built to significantly expand our company’s capabilities to support the growing industry demand by leveraging our existing expertise in DNA and RNA manufacturing. This establishes a foundation to lead the nucleic acid-based biopharmaceutical CDMO market, including gene therapies, DNA vaccines, and RNA pharmaceuticals.”